In 2025, sales are anticipated to grow by a high single-digit percentage at CER. Sanofi (SNY) confirms the expectation of a strong business EPS rebound with growth at a low double-digit percentage at CER.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi Faces EU Setback for Rezurock Amidst Positive Developments
- ImageneBio initiated with an Outperform at Leerink
- Sanofi: Buy Rating Affirmed on Strong Financials and Promising Growth Prospects
- Ventyx ‘unequivocally impressive data’ should spur Sanofi, says Clear Street
- Sanofi, Medidata expand partnership